Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Conference Call February 20, 2024 9:00 AM ET
Company Participants
Dave Gancarz - Chief Business and Strategy Officer
Bob Duggan - Chairman of the Board and CEO
Maky Zanganeh - CEO and President
Ankur Dhingra - CFO
Dr. Allen Yang - CMO
Manmeet Soni - COO
Conference Call Participants
Brad Canino - Stifel
Hartaj Singh - Oppenheimer
Operator
Good morning and welcome to Summit's Fourth Quarter and Year End 2023 Earnings Call. [Operator Instructions] Please refer to the company's website for updates. Please note that today's call is being recorded. [Operator Instructions]
At this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics Chief Business and Strategy Officer. You may now proceed, please.
Dave Gancarz
Good morning and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our forms 10-K and S-3 were also filed earlier this morning and are available on our website. Today's call is being simultaneously webcast and an archived replay will also be made available later today on our website, www.smmttx.com.
Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer; Dr. Maky Zanganeh, our Chief Executive Officer and President; Manmeet Soni, our Chief Operating Officer; Ankur Dhingra, our Chief Financial Officer; and Dr. Allen Yang, our Chief Medical Officer. Before we get started with the rest of the call, I would like to note that some statements made by our management team and some responses to questions that we may make today may be considered forward-looking statements based on our current expectations.
Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements except as required by law. Following comments from Bob, Maky, and Ankur, we will take questions.
With that, I will turn the call over to Bob.
Bob Duggan
Thank you, Dave. Good morning everyone, and thank each of you for joining us today.
I'd like to say a few words about our progress and what team Summit has accomplished. Then I will hand it over to Maky to add more color and then Ankur who will provide financial updates. It has been just one year since we closed on our partnership with Akeso and I'm very proud of the accomplishments and impressive progress team Summit has made in this period of time. Ivonescimab, our lead investigational compound and the only PD-1/VEGF bispecific antibody in Phase 3 in Summits territories, continues to actively enroll two registrational Phase 3 trials in non-small cell lung cancer are HARMONi and HARMONi-3 trials.